Clinical Trial Update: Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial compares valganciclovir with letermovir for CMV prophylaxis in heart transplant recipients and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection
• Heart Failure
• Heart Transplant Rejection

Drugs mentioned

• PREVYMIS (letermovir)
• Valcyte (valganciclovir)

Snippet

Sponsor: Columbia University | Conditions: CMV Viremia, Heart Transplant Infection | Phase 2, Phase 3 | Status: RECRUITING